Royal Bank Of Canada Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by Royal Bank Of Canada from $38.00 to $41.00 in a research report sent to investors on Thursday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

VRDN has been the topic of several other reports. HC Wainwright upped their target price on shares of Viridian Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday. Weiss Ratings raised shares of Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 14th. Truist Financial boosted their price target on shares of Viridian Therapeutics from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday. Needham & Company LLC upped their price objective on Viridian Therapeutics from $34.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Wells Fargo & Company increased their price objective on Viridian Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a research note on Thursday. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Viridian Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $41.00.

Viridian Therapeutics Stock Down 1.8%

Shares of NASDAQ:VRDN opened at $28.55 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 16.95 and a quick ratio of 16.95. The firm has a market capitalization of $3.23 billion, a PE ratio of -7.43 and a beta of 1.07. The firm’s 50-day moving average is $21.88 and its two-hundred day moving average is $21.83. Viridian Therapeutics has a 1 year low of $13.18 and a 1 year high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.21. Viridian Therapeutics had a negative net margin of 1,620.79% and a negative return on equity of 77.15%. The business had revenue of $25.75 million for the quarter, compared to analysts’ expectations of $4.72 million. Analysts predict that Viridian Therapeutics will post -4.07 EPS for the current year.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 14,212 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Viridian Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of VRDN. Integrated Wealth Concepts LLC acquired a new position in shares of Viridian Therapeutics during the second quarter worth $33,000. KBC Group NV purchased a new position in Viridian Therapeutics in the first quarter valued at $34,000. State of Wyoming purchased a new position in Viridian Therapeutics in the second quarter valued at $43,000. Fulcrum Asset Management LLP acquired a new stake in Viridian Therapeutics in the third quarter valued at $97,000. Finally, Man Group plc acquired a new stake in Viridian Therapeutics in the second quarter valued at $197,000.

More Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Multiple firms raised their price targets and maintained or initiated positive ratings. On Nov. 5, Leerink Partners lifted its target to $54 and RBC to $41, both with “outperform” ratings; Truist raised its target to $42 (“buy”), while Wells Fargo, Wedbush and HC Wainwright also increased targets. Leerink Partners rating
• Positive Sentiment: Viridian’s Q3 loss of $0.81 per share was narrower than analysts’ roughly $1.01–$1.02 estimate, and revenue of $25.75 million topped the $4.72 million consensus. The earnings beat may have helped support investor sentiment, although the per-share loss widened from $0.34 a year earlier. Q3 results
• Positive Sentiment: Viridian outlined commercial and pipeline milestones: Lumvoa’s launch is targeting broad coverage within six to nine months, and the company signaled a biologics license application for elegrobart in Q1 2027. Progress toward broader access and the regulatory filing could strengthen the growth outlook, though execution remains important. Lumvoa and elegrobart milestones
• Negative Sentiment: A separate valuation analysis argued VRDN could be overvalued even with its new product launch, which may temper enthusiasm following the rally and analyst target increases. Valuation analysis

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.